Johan M Kros Selected Research

Oligodendroglioma

1/2020	Periostin Is Expressed by Pericytes and Is Crucial for Angiogenesis in Glioma.
11/2016	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
1/2016	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas.
10/2013	MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951.
1/2013	Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
1/2011	Absence of common somatic alterations in genes on 1p and 19q in oligodendrogliomas.
3/2010	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
10/2006	1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
12/2005	Gene expression profiles associated with treatment response in oligodendrogliomas.
2/2005	Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johan M Kros Research Topics

Disease

70	Neoplasms (Cancer) 12/2022 - 08/2002
47	Glioma (Gliomas) 05/2022 - 06/2004
25	Glioblastoma (Glioblastoma Multiforme) 12/2022 - 03/2005
14	Brain Neoplasms (Brain Tumor) 10/2022 - 08/2003
12	Astrocytoma (Pilocytic Astrocytoma) 01/2022 - 03/2002
12	Oligodendroglioma 01/2020 - 03/2002
8	Medulloblastoma 11/2021 - 10/2008
6	Neoplasm Metastasis (Metastasis) 06/2021 - 10/2008
5	Adenoma (Adenomas) 01/2017 - 04/2008
4	Acromegaly 01/2017 - 01/2013
4	Pituitary Neoplasms (Pituitary Adenoma) 12/2013 - 12/2003
4	Disease Progression 01/2010 - 03/2003
3	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2014
3	Melanoma (Melanoma, Malignant) 01/2017 - 12/2003
3	Alzheimer Disease (Alzheimer's Disease) 01/2015 - 11/2011
3	Carcinogenesis 08/2012 - 04/2004
2	Aneuploidy (Aneuploid) 01/2021 - 08/2002
2	Schmid-Fraccaro syndrome 09/2018 - 01/2017
2	Growth Hormone-Secreting Pituitary Adenoma 01/2017 - 04/2008
2	Dementia (Dementias) 01/2015 - 11/2011
2	Lung Neoplasms (Lung Cancer) 12/2014 - 04/2004
2	Meningioma (Meningiomas) 08/2014 - 12/2005
2	Fragile X Tremor Ataxia Syndrome 01/2014 - 09/2006
2	Ependymoma 10/2008 - 06/2007
2	Pituitary ACTH Hypersecretion 05/2004 - 04/2003
2	Carcinoma (Carcinomatosis) 04/2004 - 04/2003
2	Ganglioglioma 08/2002 - 04/2002
1	Central Nervous System Neoplasms 01/2022
1	Infarction (Infarctions) 01/2020

Drug/Important Bio-Agent (IBA)

30	Proteins (Proteins, Gene)FDA Link 01/2020 - 03/2002
18	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 03/2005
12	Vincristine (Oncovin)FDA LinkGeneric 10/2022 - 02/2005
12	Procarbazine (Matulane)FDA Link 10/2022 - 02/2005
12	Lomustine (CCNU)FDA Link 10/2022 - 02/2005
12	Biomarkers (Surrogate Marker)IBA 06/2021 - 06/2005
10	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 03/2010
8	Messenger RNA (mRNA)IBA 06/2021 - 10/2008
8	Formaldehyde (Formol)FDA Link 02/2016 - 12/2002
8	ParaffinIBA 02/2016 - 12/2002
6	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 08/2002
5	epidermal growth factor receptor VIIIIBA 12/2022 - 12/2007
5	ErbB Receptors (EGF Receptor)IBA 01/2020 - 12/2007
5	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2017 - 04/2008
5	Calmodulin-Binding Proteins (Caldesmon)IBA 02/2009 - 08/2003
4	NucleotidesIBA 11/2021 - 10/2019
4	MethyltransferasesIBA 01/2020 - 03/2002
4	RNA (Ribonucleic Acid)IBA 10/2019 - 12/2013
4	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2017 - 04/2008
3	AntibodiesIBA 05/2022 - 06/2013
3	Bevacizumab (Avastin)FDA Link 01/2022 - 02/2016
3	Protein Isoforms (Isoforms)IBA 01/2019 - 04/2007
3	Pharmaceutical PreparationsIBA 10/2018 - 06/2007
3	Growth Hormone (Somatotropin)IBA 01/2017 - 03/2008
3	Octreotide (Sandostatin)FDA LinkGeneric 01/2017 - 04/2008
3	Monoclonal AntibodiesIBA 02/2016 - 07/2007
3	Tumor Biomarkers (Tumor Markers)IBA 01/2015 - 06/2007
3	Biological ProductsIBA 12/2013 - 12/2009
3	ProteomeIBA 06/2012 - 06/2007
2	AutoantibodiesIBA 05/2022 - 03/2003
2	AntigensIBA 05/2022 - 10/2019
2	Peptides (Polypeptides)IBA 05/2022 - 03/2008
2	Immunoglobulins (Immunoglobulin)IBA 05/2022 - 12/2002
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2020 - 12/2013
2	Tyrosine Kinase InhibitorsIBA 01/2020 - 11/2005
2	MicroRNAs (MicroRNA)IBA 11/2019 - 01/2011
2	erucylphosphocholineIBA 01/2019 - 04/2007
2	UbiquitinIBA 01/2019 - 09/2006
2	ArrestinIBA 05/2016 - 12/2013
2	ArrestinsIBA 05/2016 - 12/2013
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2016 - 01/2010
2	colligin (CBP2)IBA 10/2010 - 01/2010
2	Carmustine (FIVB)FDA Link 03/2009 - 06/2008
2	S100 Proteins (S 100 Protein)IBA 03/2009 - 04/2002
2	CollagenIBA 03/2009 - 12/2005
2	Imatinib Mesylate (Gleevec)FDA Link 10/2008 - 11/2005
2	Dopamine Receptors (Dopamine Receptor)IBA 04/2008 - 05/2004
2	Dopamine Agonists (Dopamine Agonist)IBA 04/2008 - 05/2004
2	Glial Fibrillary Acidic ProteinIBA 03/2008 - 04/2002
2	TubulinIBA 03/2008 - 04/2002
2	A-Form DNA (A-DNA)IBA 06/2007 - 03/2002
2	Alkylating AgentsIBA 03/2005 - 03/2002
2	Adrenocorticotropic Hormone (ACTH)FDA Link 05/2004 - 04/2003
1	Peptide LibraryIBA 05/2022
1	APTIBA 02/2022
1	Angiogenesis InhibitorsIBA 01/2022
1	Circulating Tumor DNAIBA 01/2021
1	Cell-Free Nucleic AcidsIBA 01/2021
1	N 30IBA 01/2021
1	Untranslated RNA (Noncoding RNA)IBA 01/2021
1	Arsenic Trioxide (Trisenox)FDA Link 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2020
1	Bicarbonates (Hydrogen Carbonate)IBA 01/2020

Therapy/Procedure

33	Drug Therapy (Chemotherapy) 10/2022 - 03/2002
23	Radiotherapy 10/2022 - 03/2003
20	Therapeutics 01/2020 - 07/2007
4	Lasers (Laser) 03/2008 - 08/2003
3	Precision Medicine 01/2020 - 07/2015
2	Chemoradiotherapy 01/2020 - 01/2016
1	Conformal Radiotherapy 01/2021
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 01/2021